Physician profile
Binal Patel
NPI 1790036325
$1,937.60
in general payments reported to CMS, 2019-2025
12 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $30.15 · 2021: $102 · 2022: $292 · 2023: $60.57 · 2024: $582 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,057.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $483.60 | 2021-2025 | Myday Contact Lens, Cvi Contact Lens |
| Alcon Vision LLC | $391.58 | 2019-2024 | Total30, Precision 1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $326.20 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $277.18 | 2022-2025 | Infuse, Xiidra, Miebo |
| Allergan, INC. | $106.92 | 2019 | |
| Oyster Point Pharma, INC. | $91.76 | 2022-2024 | Tyrvaya |
| Rxsight INC | $79.72 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Sun Pharmaceutical Industries INC. | $72.97 | 2021-2022 | |
| Zest Holdings, LLC | $38.99 | 2022 | |
| Astellas Pharma US INC | $31.17 | 2024 | Izervay |
| Novartis Pharmaceuticals Corporation | $19.19 | 2022 | |
| Biotissue Holdings INC. | $18.32 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Binal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.